Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8153869 | 0.91 | TAAR1 (0.62) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL20232206 | 0.88 | TAAR1 (0.53) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12466982 | 0.86 | MAPT (0.53) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11955598 | 0.85 | TAAR1 (0.61) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL25703682 | 0.84 | TAAR1 (0.53) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30600118 | 0.83 | TAAR1 (0.65) | TAAR1ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL12845585 | 0.83 | TAAR1 (0.65) | TAAR1ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2949402 | 0.83 | TAAR1 (0.71) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13067437 | 0.82 | TAAR1 (0.52) | TAAR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12551767 | 0.81 | TAAR1 (0.43) | TAAR1ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051762-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100285407-A1 | Composition for forming a silicon-containing antireflection film, substrate having the silicon-containing antireflection film from the composition and patterning process using the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051762-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | TAAR1 4736/4885ALDH1A1 3071/4885MAPT 3821/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | TAAR1 4512/4885ALDH1A1 1255/4885MAPT 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.